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ABSTRACT 
Rac1 GTPase interaction with guanine nucleotide exchange factor Tiam1 is involved in several cancer 
types and cardiovascular diseases. Although small molecules interfering with their protein-protein 
interaction (PPI) were identified and studied, the ability of small peptides and peptide mimics acting 
as Rac1/Tiam1 PPI inhibitors has not been yet explored. Using computational alanine scanning 
(CAS), the “hot” interfacial residues have been determined allowing the design of a small library of 
putative PPI inhibitors. In particular, the insertion of an unnatural alpha, alpha disubstituted amino 
acid, i. e. norbornane amino acid, and the side chain stapling have been evaluated regarding both 
conformational stability and biological activity. REMD calculations and CD studies have indicated 
that one single norbornane amino acid at the N-terminus is not sufficient to stabilize the helix 
structure, while the side-chain stapling is a more efficient strategy. Furthermore, both engineered 
peptides have been found able to reduce Rac1-GTP levels in cultured human smooth muscle cells, 
while wild type sequence is not active. 
INTRODUCTION 
The protein Rac1 is an ubiquitous Rho GTPase, i. e. a small monomeric protein that bounds GTP, 
which is involved in several cancer types and cardiovascular diseases.1,2 For instance, Rac1 regulates 
cellular events associated to atherogenesis, such as smooth muscle cell (SMC) migration3 and 
proliferation,4 membrane trafficking and leukocyte-endothelial cell interaction.5 Its activity depends 
on the equilibrium between inactive GDP-bound and active GTP-bound form, a cycling regulated by 
the guanine nucleotide exchange factors (GEFs) as activators, and the GTPase activating proteins 
(GAPs) and GDP dissociation inhibitors (GDIs) as negative regulators. The T-cell lymphoma 
invasion and metastasis 1 (Tiam1) protein is a specific GEF for Rac1 and is crucial for cell-cell 
adhesion and cell migration. Tiam-1 has also shown to play a pivotal role in cardiac hypertrophy 
associated to heart failure. 6  
The pharmacological inhibition of Rac1 has been first based on the interference with the prenylation 
process by using either the HMG-CoA reductase inhibitors, statins, or the prenyl transferase 
inhibitors, such as the geranylgeranyl transferase inhibitor GGTI-24187. However, both approaches 
certainly were able to affect the function of Rac1, but not in a selective manner thus inhibiting all the 
intracellular prenylated proteins. An important breakthrough in the development of selective Rac1 
inhibitors has been observed with the identification of the compound NSC23766.8 This small 
molecule fits into the surface groove of Rac1 involved in the binding with GEFs, thus interfering with 
the Tiam1-Rac1 interaction in a selective manner, without interfering with other small G proteins, 
such as Cdc-42 and RhoA. From this pioneer observation, additional and more potent selective Rac1 
inhibitors have been identified. 8–12 A second approach to selectively interfere with the cellular 
function of small G proteins is represented by the identification of compounds capable to interfere 
with the PPI between the small G protein and their effectors. ZINC69391 is able to interfere with the 
interaction of Rac1 with Dock180, a Rac1 activator in glioma invasion13. 1A-116 modulates Rac1-P-
Rex1 interaction14. Phox-I1 targets the interactive site of p67phox with Rac1 GTPase with a 
submicromolar affinity and very efficiently inhibits the ROS production in neutrophils at 20 µM 
concentration.15 EHT-1864 is another example of Rac1 inhibitor that binds Rac1 with high affinity 
compared to GDP/GTP, retaining Rac1 in an inert and inactive state16. Finally, Fasudil, the inhibitor 
of the Rho-kinase, a pivotal effector of the small G protein RhoA, has been developed and registered 
in Japan for the treatment of cerebral vasospasm after surgery in subarachnoid hemorrhagic patients.17  
Although small molecules dominated the drug industry in the last century, a raising interest has been 
observed in the recent years toward peptide drugs.18,19 Indeed, peptides can help to overcome some 
of the main questions that make a small molecule candidate fail during the latest phases of the drug 
development pipeline, in particular toxicity and tolerability.19 Conversely, peptides are considered 
rather safe and well tolerated, and their metabolic course is easily predictable. Furthermore, libraries 
of peptides can be easily synthetized, starting by readily available and generally non-expensive 
building blocks represented by both natural and non-natural amino acids. Moreover, when targeting 
PPIs, peptides represent the “natural” PPI interface partners, and an active peptide can thus be 
considered an excellent starting point for future development of bioactive compounds.20,21,22,23 On the 
other hand, a common drawback of  natural peptides is that they often show a low metabolic stability. 
Furthermore, the high conformational freedom of small peptides might play against potency, since 
the reduction of entropy upon association with the target protein reflects on a higher binding free 
energy.24 However, the use of non-natural amino acids or simple chemical modifications to the 
peptide structure can help in overcoming these disadvantages.25 
For the above reasons, we were interested in providing an alternative to the already available small 
molecules, which might be used as a lead to develop new potent, selective and safe compounds acting 
as inhibitors of the Rac1-Tiam1 PPI. Starting from a helical peptide segment derived from the 
sequence of Tiam1 that interacts with Rac1, we designed a small peptide library. In particular, the 
insertion of an unnatural alpha, alpha disubstituted amino acid, i.e. norbornane amino acid,26 and the 
side chain stapling27,28,29 have been evaluated as strategies to obtain engineered peptides. Indeed, 
these approaches might lead to peptides that are stable to metabolism, inherently stable to proteases 
and peptidases, and can fold into well-ordered secondary structures.30 
MATERIALS AND METHODS 
Molecular modelling 
The starting geometry of the Tiam1-Rac1 complex was downloaded from the Protein Data Bank 
(PDB file 1FOE),31 GDP and the coordinated Mg ion were transferred into the Rac1 catalytic site 
from the crystal structure of GDP-bound Rac1 complexed with P21 (PDB file 1I4D).32 The “Structure 
Preparation” module of the MOE software33 was then used to cap the N- and C-terminus by acetyl 
and methylamino groups, to replace selenomethionine by methionine and to reconstruct residues with 
missing atoms. The system was then protonated at pH = 7 by using the “Protonate 3D” module of 
MOE. Then it was minimized up to a gradient of 0.1 kcal mol-1 Å-1 using the AMBER10EHT force 
field and the Born solvation model, implemented in MOE, by keeping the backbone atoms 
constrained to the original position. The system was then loaded into the leap module of the 
AmberTools16 package,34 and solvated by an octahedral box of TIP3P water molecules.35 Force field 
parameters were assigned based on the ff99SB force field,36 while GDP parameters were obtained 
from the Amber Parameters Database.37 The system was then equilibrated by multiple steps of 
minimizations, NVT and NPT equilibrations, as reported in previous works.38–40A NPT production 
run of 12 ns was conducted with the pmemd module of the Amber16 suite.34 The same protocol was 
adopted for the simulation of complexes between Rac1 and designed peptides. The trajectories were 
analyzed by using the cpptraj module of AmberTools16. 
Molecular Mechanics Generalized Born (MM-GBSA) calculations and computational alanine scan 
(CAS) analyses were performed on the last 4 ns of production trajectories by using the MMPBSA.py 
script included in the AmberTools suite.41 The OBC(II) solvent model with a saline concentration of 
0.15 M was requested.42 Calculations were performed on 100 evenly spaced snapshots extracted from 
the solvated trajectory and the entropy contribution was neglected. 
Replica exchange molecular dynamics (REMD) simulations43 on designed peptides were performed 
by adapting previously reported protocols.44–51 The combination of the ff99SB force field and the 
OBC(II) model was requested, and 20 replica were run for 100 ns at temperatures spanning from 
270.0 to 654.5 K (see Table S1, Supporting Information for details). Parameters for non-natural amino 
acids were derived as described previously. 44,45 Analyses were performed with cpptraj on the REMD 
trajectory reconstructed at 296.7 K. Cluster analyses were done by using the average-linkage 
algorithm sampling one every two frames. A total of five cluster were requested and the pairwise 
mass-weighted Root Mean Squared Displacement (RMSD) was used as a metric. The analysis was 
performed periodically and the simulation was considered converged when the difference in 
population for the principal cluster between two consecutive blocks of 25 ns was below 10%. 
Peptide synthesis 
Fmoc Rinkamide resin, Fmoc-protected amino acids, HBTU, HOBT and DIEA were purchased from 
Iris Biotech Gmbh (Germany). Solvents, piperidine and other reagents were purchased from Sigma-
Aldrich (Germany). All peptides were synthesized using a CEM Liberty peptide synthesizer and 
purified using RP-HPLC with a Jasco BS-997-01 instrument and a DENALI C-18 column from 
GRACE VYDAC (10µm, 250  22 mm). ESI mass spectra were recorded on a LCQ Advantage 
spectrometer from Thermo Finnigan. 
Linear peptides synthesis. Linear peptides were prepared by Fmoc based microwave assisted solid 
phase synthesis.52 The peptides were assembled on Fmoc Rinkamide (0.4 meq/g substitution) using 
a 5-fold molar excess of Fmoc-protected amino acids dissolved (0.2 M in NMP) and 
HOBT/HBTU/DIEA (5:5:10) as coupling reagents. Coupling reactions were performed for 5 min at 
40 W with a maximum temperature of 75°C. Deprotection was done in two steps using 20% 
piperidine in DMF (5 min and 10 min each).  
Coupling of Norbornane amino acid. (1R, 2R, 4R) N-Ac-Nrb-OH26 (2 eq) dissolved in DMF was 
added to the N-deprotected peptide on resin. HOBt (2 eq) and DIC (2 eq) were added and the mixture 
was stirred for 12 hours (coupling repeated twice until negative Kaiser test). 
N-Terminus acetylation. Synthesized peptides were N-terminus manually acetylated on resin using 
acetic anhydride (10 eq) and DIPEA (10 eq) in DCM for 30 min swelling at room temperature. 
N-Terminus Fitc-conjugation. The labelling was performed on resin, before the cleavage, using 5(6)-
carboxyfluorescein (10 eq) and HOBT/DIC (10 eq) as coupling reagents. The coupling reaction was 
performed twice (1 hour each one) in the dark under vigorous shaking. 20% piperidine in DMF was 
then added and the mixture was shaken for 1 hour.  
Removal of Alloc-Orn and Allyl-Asp protecting groups. A solution of PhSiH3 (24 eq) in anhydrous 
DCM was added to the N-acetylated peptide on resin. The mixture was stirred for 2 min under 
nitrogen. Pd(PPh3)4 (0.5 eq in anhydrous DCM) was added to the vessel and the reaction was left 
under stirring for 1.5 h. The procedure was repeated twice. Finally, the resin was washed with DMF 
and DCM. 
On resin side chain Asp-Orn cyclization. After Orn and Asp side chain deprotection, the resin was 
swelled in NMP. A solution of HOBt/HBTU (6 eq) in DMF was added to the reaction vessel. DIPEA 
(12 eq) was added. The reaction was left under stirring for 2 h. The procedure was repeated until the 
Kaiser test was negative. 
Cleavage from the resin. Cleavage was performed using 10 ml of Reagent K 
(TFA/phenol/water/thioanisole/EDT; 82.5/5/5/5/2.5) for 180 min. After cleavage, peptides were 
precipitated out and washed using ice-cold anhydrous ethyl ether. All peptides were purified by RP-
HPLC using a gradient elution of 5–70% solvent B (solvent A: water/acetonitrile/TFA, 95/5/0.1; 
solvent B: water/acetonitrile/TFA, 5/95/0.1) over 20 min at a flow rate of 20 ml/min. The purified 
peptides were freeze-dried and stored at 0°C and analysed using analytical HPLC (95% A for 5 min.; 
95-30% A over 20 minutes) and ESI mass spectrometry (see Supporting Information). 
Circular Dichroism  
Circular dichroism spectra were collected using a Jasco J-800 spectropolarimeter. The spectral scans 
were collected between 250 and 190 nm, 0.1 nm data pitch, at 50 nm/min scanning speed. Each 
spectrum is the result of 3 averaged accumulations. 100 M peptide stock solutions were prepared in 
HPLC grade water and then diluted to 20 M final concentration with water or trifluoroethanol (TFE). 
The CD spectra were plotted as mean residue ellipticity  (degree x cm2 x dmol-1) versus wavelength 
 (nm). Noise-reduction was obtained using a Fourier-transform filter program from Jasco. 
Cell Culture and G-LISA assay.  
Human SMCs (A617 from human femoral artery) were grown in monolayers at 37 °C in a humidified 
atmosphere of 5% CO2 in DMEM supplemented with 10% (v/v) FCS, 100 U/mL penicillin, 0.1 
mg/mL streptomycin, and nonessential amino acids. The medium was changed every third day. For 
the experiments cells were seeded at a density of 2 ×105/35 mm Petri dish and incubated with DMEM 
supplemented with 10% FCS; 24 h later the medium was changed to one containing 0.4% FCS, and 
the cultures were incubated for 48 h. At this time, the peptides were added to the cultured medium, 
and after 4 h the intracellular amounts of Rac1−GTP were determined by using the G-LISA assay, as 
previously described12  
Cellular uptake of the fluorescence-labeled peptide 
After 72 hours incubation with increasing concentrations of peptide, the cells were trypsinized and 
centrifuged for 5 min at 1,000 rpm. Pellets were resuspended in 0.5 mL PBS and the fluorescence 
signal was recorded on the FL2 channel of a FACS scan flow cytometer (Becton Dickinson) and 
analyzed with ModFit LT software (Verity Software House, Topsham, ME, USA). The cellular 
uptake of the peptide was expressed as mean florescence index (MFI) of 10,000 cells per sample. 
Statistical analysis 
Data are expressed as mean ± SD. Student's t test was used to evaluate differences between groups, 
and statistical significance was assigned when P < 0.05. 
 
RESULTS AND DISCUSSION 
Design of engineered peptides. Tiam1 interacts with Rac1 through two helices, CR1 and CR3, and 
through the C-terminal portion of helix α9 (Fig 1A) of the DH domain (AAs 1034-1258). On the 
Rac1 side, interactions with Tiam1 are mediated by two loops, switch 1 (AAs 25-39) and switch 2 
(AAs 57-75), and by non-conserved residues between switches, ensuring proper GEF/Rac1 pairing.31 
The comparison between the Rac1-Tiam1 complex and the crystal structure of a Zn-stabilized Rac1-
GDP complex shows that the binding with Tiam1 alters the conformation of switches 1 and 2 thus 
reducing the affinity for Mg ion and favoring GDP-GTP exchange (Fig 1B).32 
 
Figure 1. A) Crystal structure of Tiam1-Rac1. DH domain of Tiam1 and Rac1 are represented as 
grey and pink ribbons. Rac1 “switch 1” and “switch 2” are magenta and green, respectively. Tiam1 
residues calculated as “hot-spots” and “warm-spots” are red and cyan, respectively. In orange is 
represented the Tiam1 sequence containing the largest number of consecutive hot and warm spots 
(AAs 1187-1199 of CR3 helix). B) Superposition of crystal structures of Tiam1-bound (pink) and 
GDP-bound (tan) Rac1 complexes. 
Interactions with switch 1 are mediated by CR1, while interactions with α9 helix seem to be 
responsible of the altered conformation of switch 2. The CR3 helix of Tiam1 is sandwiched between 
switches 1 and 2 and interacts with the flanking regions of both loops and with residues between 
them, including W56 which is important in the binding with small molecule inhibitors.8  
Starting from the Rac1-Tiam1 crystal structure, we performed MD simulations followed by 
computational alanine scanning (CAS) analyses using the molecular mechanics generalized Born 
(MM-GBSA) approach. CAS allows evaluating the variation in binding free energy (ΔΔGb) following 
the mutation to Ala of selected interfacial residue. A total of 52 Tiam residues lying at the contact 
interface with Rac1 (from Leu1035 to Glu1240; see Table S2, Supporting Information for the full list 
of residues and computed ΔΔGb) were evaluated in the CAS analysis. Interfacial AAs were classified 
as hot-spots when the computed ΔΔGb was > 4 kcal/mol, warm-spots where 2 < ΔΔGb < 4 kcal/mol 
and cold-spots where ΔΔGb < 2 kcal/mol (Table 1 and Fig.1A).  
Table 1. Hot- and warm-spots from CAS analysis of CR3 helix of Tiam1 complexed with Rac1. Free 
Energy Differences in Binding Energy (ΔΔGb) upon Mutation of the Selected Residues to Alanine are 
Reported in kcal/mol. 
Residue ΔΔGb 
I1187 4.5 
K1188 7.5 
Q1191 7.9 
L1194 4.1 
K1195 3.8 
L1198 2.4 
L1199 2.8 
 
Energy values reported in Table 1 fit well with the qualitative analysis of Worthylake et al.31 and 
confirm that the Rac1-Tiam1 interaction is principally exerted by a 13 residue long helix belonging 
to CR3 (hereafter referred as I1187-L1199 and colored in orange in Fig.1). Since I1187-L1199 seems 
to mediate Tiam1-Rac1 interaction, but not the conformational change leading to GDP-GTP 
exchange, we took it as the starting point for the design of inhibitor peptides. (1-5) (2-6) 
Two wild type (WT) peptides of 9 and 13 amino acids, WT9 and WT13 (Table 2), with acetyl and 
methylamino caps at the N and C-termini, were designed in complex with Rac1 and subjected to 12 
ns of MD simulation. The former peptide contains all residues comprised by the hot-spots I1187 and 
K1195, while the second also includes the two warm-spots L1198 and L1199. The geometry of both 
peptides corresponds to that found in the crystal structure.31 The binding energy was then calculated 
by MM-GBSA on the last 4 ns of the trajectory and resulted in -31.5 ± 5.7 kcal/mol and -41.0 ± 5.5 
kcal/mol for WT9 and WT13, respectively (Table 2). Since WT13 scored a lower binding energy and 
a lower standard deviation, suggesting that it is able to better stabilize the complex with Rac1, it was 
selected as the starting point for the design of modified peptide. First, considering that the CR3 
sequence interacting with Rac1 is helical, we evaluated the conformational preferences of WT13, 
since its excision from Tiam1 could hardly allow the maintainment of its native helical conformation. 
Indeed, REMD simulations, followed by cluster analysis, showed that only the central portion of the 
peptide maintained a helical secondary structure, while the first two residues at the N-terminus and 
the last four at the C-terminus, were disordered (Fig. 2A). Aiming to stabilize the helical 
conformation, without affecting the binding capabilities of the peptide to Rac1, we evaluated the 
mutation of the N-terminal I1187 to the non-natural amino acid NRB (Fig. 2B), which in previous 
theoretical works showed a discrete capability of stabilizing α-helices46 and a good propensity in 
inducing a right-handed helix screw sense.47 Among other non-natural amino acids, NRB was also 
chosen as a mimetic of aliphatic apolar amino acids. However, REMD simulation of the mutated 
peptide M1 did not provide the expected results, since the α-helix was only marginally stabilized 
(Fig. 2B). On the other hand, MM-GBSA calculations conducted on the Rac1/M1 complex showed 
an improved binding energy (Table 2). 
Codice campo modificato
 Figure 2. Superimposition of the crystal geometry of WT13 segment (orange) with the most 
representative geometries of: A) WT13 peptide (green) B) M1 (blue) and C) M2 (red) obtained by 
REMD simulations and cluster analysis. 
We decided to evaluate theoretically a second mutant peptide (M2) were both I1187 and P1197 were 
replaced by NRB (Fig. 2C). In this case, REMD simulations and cluster analyses showed a significant 
improvement in the stabilization of the helical secondary structure. On the other hands, binding 
energies comparable to the WT13 peptide were obtained (Table 2).  
Table 2. Binding energies (kcal/mol) calculated by MM-GBSA for peptides WT9, WT13, M1 and 
M2 
Peptide EMM-GBSA Sequence 
WT9 -31.5 ± 5.7 Ac-IKPIQRVLK-CONH2 
WT13 -41.0 ± 5.5 Ac-IKPIQRVLKYPLL-CONH2 
M1 -52.4 ± 9.2 Ac-(Nrb)KPIQRVLKYPLL-CONH2 
M2 -36.7 ± 5.6 Ac-(Nrb)KPIQRVLKY(Nrb)LL-CONH2 
 
Unfortunately, the synthesis of M2 peptide resulted challenging due to the low reactivity of NRB 
amino acid on solid phase that hampered its obtainment in significant amount for characterization 
and biological tests. We thus decided to follow a different approach to stabilize the secondary 
structure of the peptide, i.e. stapling the sidechains of some residues not involved in the binding.27,28 
Following suggestions from CAS analysis, we mutated in silico, using the MOE software, the cold-
spots R1192 and Y1196 to ornithine (Orn) and aspartate, respectively. This mutation provided 
complementary sidechains at the correct distance to form an amidic bond. The two side chains were 
then linked and the geometry was optimized with MOE (AMBER10EHT force field, Born solvation 
model.33 We observed that no dramatic variation in the backbone conformation occurred (Fig. 3), so 
the stapled peptide ST was selected for synthesis and biological evaluation, together with WT13 and 
M1. 
 
Figure 3. Sequence and minimized geometry of the stapled peptide ST. 
Peptide synthesis 
WT13 peptide sequence and the two engineered sequences containing (1R,2R,4R) N-acetyl 
norbornane (NRB) amino acid 26 in position 1 (M1 peptide) and the stapling between position 6 and 
10 (ST peptide) have been chemically synthesized on Rink amide resin using microwave assisted 
solid phase peptide synthesis52 (Table 3). 
 
Table 3 Synthesized peptide sequences and overall yields 
 
 
 
 
 
 
 
 
Coupling reactions were performed using a five fold excess of Fmoc-amino acids, using 
HOBT/HBTU as activators and DIPEA as the base. In the case of stapled peptide ST, Alloc and Allyl 
Peptide Sequence Yield (%) 
WT13 Ac-IKPIQRVLKYPLL-CONH2 40 
Fitc-WT13 Fitc-IKPIQRVLKYPLL-CONH2 30 
M1 Ac-(Nrb)KPIQRVLKYPLL-CONH2 15 
ST 
 
30 
protecting group have been used for side chain protection of Ornithine 6 and Aspartic acid 10, 
respectively. After linear ST peptide synthesis, the side chain deprotection has been performed using 
Pd(Ph3)4 and PhSiH3.53 Cyclization has been done using HOBt/HBTU and DIPEA in NMP. In the 
case of M1 peptide, norbornane coupling has been performed manually using N-Ac-Nrb (2 eq), 
HOBT/DIC (2 eq) and a double coupling protocol (12 hours for each coupling). In order to perform 
cell internalization studies, fluo-labelled Fitc-WT13 peptide has been also prepared (Table 3). 
Circular dichroism (CD) 
The secondary structures of WT13, ST and M1 peptides have been studied using circular dichroism 
(CD). In water, WT13 peptide is present as a mixture of different conformations as indicated by the 
negative Cotton effect below 200 nm (Figure 4A). The addition of 50% trifluoroethanol (TFE) leads 
to an increase of the WT13 helical content (positive band at 190 nm and two negative shoulders at 
208 and 222 nm). A similar trend is observed also for the stapled ST peptide (Figure 4B), although 
in 50% TFE the helical stabilization seems higher (more intense positive * and negative n-* 
amide transition bands). M1 peptide shows, instead, completely different CD spectra (Figure 4C). In 
water, M1 spectrum is characterized by a negative Cotton effect at 190 nm and by a strong positive 
band at around 208 nm, suggesting a major contribution of the turn secondary structure to the overall 
conformation of the peptide. The spectrum does not change by varying both the pH and the 
temperature (data not shown). The addition of 50% TFE leads to a decrease of the intensity of the n-
* amide transition band, probably indicating the increase in other conformations. These data 
confirmed the REMD calculations that indicated that the presence of only one NRB residue at N-
terminus is not enough to stabilize helix structure (see before).   
 
 Figure 4. CD spectra in water (red line) and 50% TFE (black line) of a) WT13, b) ST and c) M1 
peptides 
In order to investigate the pharmacological inhibition of Rac1 by the selected peptides, we first 
evaluated the capacity of WT13 to diffuse across the plasma membrane. By using labelled Fitc-
WT13, we detected a nice concentration-dependent cellular uptake by flow-cytometry analysis, 
demonstrating the capability of this peptide to be uptake by the cells and potentially reaching its 
intracellular target (Figure 5).  
Figure 5. Cellular uptake of Fitc-WT13. Smooth muscle cells were seeded at a density of 2 × 105/35 
mm Petri dish and incubated with DMEM supplemented with 10% FCS; 24 h later the medium was 
changed to one containing 0.4% FCS, and the cultures were incubated for 48 h. At this time, the 
fluorescence-labeled analog of Fitc-WT13 was added to the cultured medium at indicated final 
concentrations. After 6 h, cell fluorescence were determined by flow-cytometry analysis. 
The pharmacological inhibition of Rac1 was then tested by performing a series of experiments on 
cultured primary human smooth muscle cells, and determining the Rac1-GTP levels by G-LISA 
assay. As shown in Figure 6, M1 and ST peptides significantly reduced Rac1-GTP levels at both 25 
and 100 µM, while WT13 was inactive and Fitc-WT13 led to a partial inhibition only at 100 µM. 
The IC50 value cannot be calculated since the peptides did not reduced the Rac1-GTP levels by more 
than 50%, but it is relevant to point out that, under the same experimental condition, the Rac1 inhibitor 
NSC23766 showed, in our previous study, only an 11.1% reduction of Rac1-GTP at 50µM 
concentration, while M1 and ST peptides, at the same concentration, inhibited Rac1-GTP, 
respectively by 30.5% and 43.3%.9 Thus suggesting that the peptides elicited a significant inhibitory 
effect on Rac1 with comparable potency than NSC23766. 
Figure 6. Effect of selected peptides on intracellular levels of Rac1-GTP levels. Smooth muscle cells 
were seeded at a density of 2×105/35 mm Petri dish and incubated with DMEM supplemented with 
10% FCS; 24 h later the medium was changed to one containing 0.4% FCS, and the cultures were 
incubated for 48 h. At this time, the peptides were added to the cultured medium at a final 
concentration of 25 and 100 μM, and after 4 h Rac activation was induced by PDGF-BB (20 ng/mL) 
for 2 min. Total protein extracts and G-LISA assays were then performed. *p<0.05; **p<0.01 vs 
basal.  
Although the actual mechanism of action of these peptides still needs to be defined, the fact that we 
have observed a significant inhibition of Rac1-GTP levels after the stimulation with PDGF-BB, 
strongly suggest their capability to interfere with the exchange between GDP and GTP. Nevertheless, 
additional experiments are required in order to define their selectivity of action towards the inhibition 
of PPI between Rac1 and Tiam1 or other GEFs 
CONCLUSION 
Starting from Rac1-Tiam1 protein-protein interface, a small library of peptides as putative PPI 
inhibitors has been designed. Their conformational behavior was investigated by REMD calculations 
and their binding energies calculated in silico using MM-GBSA approach. The introduction of an 
unnatural amino acid, i.e. NRB, at the N-terminus on wild type sequence was not sufficient to stabilize 
the helical conformation, while side-chain amide stapling increased the helix character, as confirmed 
by CD studies on synthesized peptides. The biological effect on Rac1 was investigated by the 
determination of Rac1-GTP levels by G-LISA assay on cultured primary human smooth muscle cells. 
Both the engineered peptide M1, containing NRB amino acid, and the stapled one ST significantly 
reduced Rac1-GTP levels at both 25 and 100 µM. Although we are aware that the activity of both 
peptides is lower than that of currently available small molecules, we think that M1 and ST might 
represent an interesting alternative for the development of new Rac1 inhibitors targeting Rac1-Tiam1 
interface. 
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